This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
IFNB1 / Interferon beta · Western blot design guide
Design a Western Blot for IFNB1
Real validated IFNB1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-IFNB1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
IFNB1 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~22.3 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Glycosylated + Phosphorylated | |
| Caveat | Modification-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated IFNB1 Western Blot Protocols
The A02041-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | 5 μg/mL and, 10 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution (catalog A02041-1) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A02041-1 · 5 μg/mL (catalog A02041-1) |
| Primary incubation | 1h (catalog A02041-1) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected IFNB1 Western Blot Band Size?
IFNB1 has a predicted 22.3 kDa precursor; signal-peptide cleavage and Asn101 glycosylation may affect migration, but no empirical band size demonstrates either effect.
| Band near 22.3 kDa | Compatible with the predicted precursor mass; identity requires controls |
| Band below 22.3 kDa | Could reflect removal of the 1–21 signal peptide |
| Band above 22.3 kDa | N-linked glycosylation at Asn101 could contribute, but a visible shift is unestablished |
| Little or no band in whole-cell lysate | IFNB1 is secreted |
💡Expected IFNB1 appearanceUniProt predicts a 22.3 kDa precursor; signal-peptide removal and N-linked glycosylation may alter migration, but no empirical band size is supplied, so verify identity with appropriate controls.
| Predicted precursor mass | Provides a 22.3 kDa reference, not a validated band position |
| Signal peptide at residues 1–21 | Cleavage reduces the peptide mass of the mature protein |
| N-linked glycosylation at Asn101 | May increase apparent size; the magnitude is unknown |
| Possible Asn101 glycan occupancy differences | Could produce differing migration if occupancy varies; distinct bands are unestablished |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | IFNB1 is secreted | Check conditioned medium alongside lysate |
| Band higher than expected | Asn101 glycosylation is possible, but band identity is uncertain | Compare deglycosylated and untreated samples with a specificity control |
| Band lower than expected | The 1–21 signal peptide may have been removed | Compare precursor and mature-protein controls where available |
| Multiple bands | Precursor processing or differing Asn101 glycan occupancy is possible | Compare conditioned medium and lysate, then assess deglycosylation and antibody specificity |
| Weak or no signal | Secreted IFNB1 may be scarce in the sampled fraction | Test conditioned medium and include a positive control |
Experiment evidence
Western blot images showing IFNB1 band
A02041-1 · IFNB1
A02041-1 · IFNB1
M02041 · IFNB1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for IFNB1 Western blot
🧪For positive controls for IFNB1 in Western blot, you can use no HPA-supported positive tissue or cell line from the supplied data.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: IFNB1 is secreted, so conditioned medium may give a clearer signal than whole-cell lysate; the supplied HPA data identify no positive sample.
HPA tissue expression evidence for IFNB1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced IFNB1 Western Blot Tips
Deeper troubleshooting and optimisation questions for IFNB1, answered from its protein features.
How should IFNB1 band migration be interpreted?
Band shift · Use the separately labelled calculated mass and catalog-observed evidence above. A sequence annotation does not establish an observed migration shift. Verify target identity with orthogonal controls.
Could annotated isoforms explain multiple IFNB1 bands?
Isoforms · The supplied UniProt record lists one isoform and no alternative sequence. It therefore provides no annotated isoform explanation for multiple bands. Assess bands in light of signal peptide processing, the Asn101 glycosylation site, and antibody specificity without assigning an identity from position alone.
How should IFNB1 glycosylation be considered when interpreting bands?
PTM · UniProt lists one N-linked glycosylation site at Asn101, using precursor sequence numbering. Consider glycosylation when comparing band positions, but the listed site does not establish whether a particular sample is glycosylated or whether its band shifts.
UniProt lists phosphotyrosine at Tyr24, using precursor sequence numbering; the signal peptide spans residues 1–21. If assessing phosphorylation, use Tyr24 in that numbering convention when checking reagent specificity. The annotation alone does not establish phosphorylation in a given sample or a visible band shift.
UniProt lists phosphotyrosine at Tyr24, using precursor sequence numbering; the signal peptide spans residues 1–21. If assessing phosphorylation, use Tyr24 in that numbering convention when checking reagent specificity. The annotation alone does not establish phosphorylation in a given sample or a visible band shift.
Does this guide establish induction of IFNB1?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for IFNB1?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02041-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
What should be controlled when quantifying IFNB1 by Western blot?
Quantitation · Because IFNB1 is secreted, compare the same sample fraction across conditions and account for differences in the amount of medium collected. Quantify a consistently identified IFNB1 band; the supplied features do not establish that every detected band represents the same protein form.
Why might IFNB1 migrate differently from its predicted 22.3 kDa?
Interpretation · The 22.3 kDa prediction refers to the 187-residue precursor. IFNB1 has a signal peptide at residues 1–21 and an N-linked glycosylation site at Asn101, so processing and glycosylation are relevant when assessing apparent mass. These features alone do not establish a visible shift or explain any particular band.
UniProt identifies IFNB1 as secreted and lists a signal peptide at residues 1–21. Include culture medium when assessing secreted IFNB1; a cell lysate alone may not represent all detectable protein.
UniProt lists one disulfide bond and describes IFNB1 as a monomer. Keep sample preparation conditions consistent when comparing bands, but the bond annotation alone cannot identify an unexpected band or establish a mass shift.
UniProt identifies IFNB1 as secreted and lists a signal peptide at residues 1–21. Include culture medium when assessing secreted IFNB1; a cell lysate alone may not represent all detectable protein.
UniProt lists one disulfide bond and describes IFNB1 as a monomer. Keep sample preparation conditions consistent when comparing bands, but the bond annotation alone cannot identify an unexpected band or establish a mass shift.
Boster reagents
IFNB1 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-IFN-beta IFNB1 Antibody
Cat # A02041-1
Real WB data
Anti-Interferon beta Rabbit Monoclonal Antibody
Cat # M02041
Two the supplier anti-IFNB1 antibodies have WB images: A02041-1 in mouse A20 cell lysate (15 μg per lane; 5 or 10 μg/mL primary) and M02041 in HeLa cell lysate. These images show tested contexts, not broad validation.
Which to pick: For mouse samples, A02041-1 lists mouse reactivity and shows an A20 WB. For human samples, both list human reactivity; M02041 shows a HeLa WB. A02041-1 also lists rat reactivity, but no rat WB image is supplied.
Source: BosterBio IFNB1 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P01574.
- Human Protein Atlas. IFNB1 tissue expression.
- PMC13583594 — target-verified WB comparison